MedPath

Ariad Pharmaceuticals, Inc.

Ariad Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
1991-01-01
Employees
459
Market Cap
-
Website
http://www.ariad.com

Resolution Therapeutics Secures $83 Million to Advance Macrophage Therapy for End-Stage Liver Disease

• Resolution Therapeutics has secured $83 million in Series B financing to advance RTX001, a novel macrophage therapy, into clinical trials for end-stage liver disease. • The EMERALD Phase I/II trial, evaluating RTX001, is set to begin in the UK and Spain in Q4 2024, marking a significant step for this potential first-in-class treatment. • The funding will also support the expansion of Resolution's macrophage therapy platform into other inflammatory and fibrotic conditions, including graft-vs-host disease. • Paul Sekhri, a seasoned life sciences executive, has been appointed as Chair of the Board of Directors, bringing extensive experience to guide Resolution's growth.
© Copyright 2025. All Rights Reserved by MedPath